Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19

METUCHEN, N.J., Oct. 14, 2020 /PRNewswire/ — Tevogen Bio, today announced that its Investigational New Drug (IND) application to develop a COVID-19 treatment using proprietary antigen specific T cel… [read more]

Leave a Comment